Related Experiment Videos
HLA class I expression in primary hepatocellular carcinoma
Jian Huang1, Mei-Ying Cai, Da-Peng Wei
1Bioinfo Tech Incorporated Company, 10F Zhuangsen No.8 Dongsheng Street, Chengdu 610015, Sichuan Province,China. huangjian@bioinfochina.com
World Journal of Gastroenterology
|August 14, 2002
Summary
Hepatocellular carcinoma (HCC) cells strongly express Human Leukocyte Antigen (HLA) class I antigens. This suggests that CTL vaccine therapy is a suitable and practical approach for treating HCC.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer.
- Human Leukocyte Antigen (HLA) class I antigens play a role in immune responses.
- Cytotoxic T-lymphocyte (CTL) vaccine therapy is an emerging cancer treatment.
Purpose of the Study:
- To evaluate the expression of HLA class I antigens in HCC.
- To determine the suitability of CTL vaccine therapy for HCC based on HLA class I antigen expression.
Main Methods:
- Immunocytochemistry and immunohistochemistry (LSAB method) were used to analyze 4 HCC cell lines and 6 HCC tissue specimens.
- Flow cytometry and image analysis quantified HLA class I antigen expression.
- Raji (positive control) and K562 (negative control) cell lines were used for comparison.
Main Results:
- HCC cell lines and HCC tissues exhibited strong positive staining for HLA class I antigens.
- Normal hepatocytes showed weak or no staining, while liver sinus staining was strong.
- Flow cytometry and image analysis confirmed significant HLA class I antigen expression in HCC cells compared to K562 cells (P<0.01).
Conclusions:
- HCC cells demonstrate robust expression of HLA class I antigens.
- The findings support the suitability and practicality of CTL vaccine therapy for HCC treatment.